CompletedPhase 2ketamine

Ketamine to Improve Recovery After Cesarean Delivery - Part 1

Sponsored by Grace Lim, MD, MS

NCT ID
NCT04037085
Target Enrollment
8 participants
Start Date
2019-10-09
Est. Completion
2021-08-01

About This Study

The objective of this study is evaluate the breastmilk transfer and pharmacokinetics (Part 1) and effectiveness (Part 2) of a post-cesarean delivery intravenous ketamine bolus-and-infusion strategy, as a preventive analgesic modality to reduce pain and opioid requirements. In Part 1, physiochemical analysis of pharmacokinetic/pharmacodynamic (PK/PD) and breastmilk transfer of ketamine and its metabolites will be assessed. Additionally calculated estimations for neonatal and infant exposure will be assessed. In Part 2, PK/PD assessments will continue in a larger cohort; endpoints will also include postpartum pain, depression scores, central sensitization measures, patient-reported postpartum recovery scores, breastfeeding, and parent-infant bonding, assessed in the acute post-cesarean period and up to 12 weeks postpartum in a randomized controlled trial.

Conditions Studied

Obstetric PainPostpartum DepressionBreastfeedingPain, AcutePain, ChronicObstetric Anesthesia ProblemsDrug EffectOpioid Use

Interventions

  • Ketamine

Eligibility

Sex:FEMALE
Age:18 Years - 99 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria:

* Adult female patients (i.e., ≥18 years of age) and able to provide informed consent
* Cesarean Delivery, Scheduled or Non-Emergent (delivery within 15 minutes not necessary), or female weaning off of breastfeeding
* Cesarean cohort: ASA PS 2 or 3, with or without E designation (delivery within 15 minutes not necessary), Scheduled or Non-Emergent
* Spinal anesthesia with intrathecal morphine if Cesarean Delivery, Scheduled or Non-Emergent
* Multimodal postop analgesia with IV ketorolac, PO NSAID, and PO APAP if Cesarean Delivery, Scheduled or Non-Emergent
* Women who do not plan to breastfeed or who want to temporarily withhold breastfeeding or who are weaning off of breastfeeding (Part 1)

Exclusion Criteria:

* Cesarean Delivery under General Anesthesia
* Allergies to study medications
* ASA PS 4 or 4E
* ASA PS with E designation because delivery within 15 minutes required
* ASA PS greater than 4 (moribund patients)
* Contraindications to spinal anesthesia
* Contraindications to NSAIDs (gastric bypass, etc.)
* Contraindication to any other multimodal analgesia medicine
* Significant psychiatric history (depression and anxiety NOT exclusion criteria), uncontrolled hyperthyroidism, cardiac disease, fever, hypertension
* Adverse occurrence during caesarean section such as hemorrhage, need for transfusion, hemodynamic instability
* Placenta accreta spectrum or previa with large anticipated blood loss
* History of hallucinations, alcohol or illicit substance use/abuse, chronic opioid therapy, or chronic pain (chronic pain - defined by any condition requiring consistent follow up with pain specialist or daily administration of pain medications that could augment sedative effects)
* Pre-eclampsia with severe features

Study Locations (2)

UPMC Montefiore Hospital CTRC
Pittsburgh, Pennsylvania, United States
Minhnoi C Wroble Biglan
Pittsburgh, Pennsylvania, United States

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Ketamine to Improve Recovery After Cesarean Delivery - Part 1 | Huxley